Palpitations: Evaluation, Management, and Wearable Smart Devices – Study Notes (Am Fam Physician 2024)

Overview

• Palpitations: patient-described sensation of racing, fluttering, pounding, irregular or skipped heartbeats, or a neck-pounding feeling. Common symptom with low mortality but can impair quality of life and drive increased health-care use.
• Triggers fall into: cardiac disorders; endocrine/metabolic disorders; medication or illicit drug use; psychosomatic disorders.
• Primary approach: detailed history, focused physical examination, directed laboratory studies, and a 12-lead ECG often identify etiology. Additional testing (echo, cardiac stress testing, ambulatory ECG monitoring, or electrophysiologic studies) used to distinguish whether symptoms reflect arrhythmia, structural heart disease, or ischemia.
• Management is etiology-based:
  • Cardiac-induced palpitations: reassurance, patient education, trigger avoidance, and potentially atrioventricular nodal blockers; tachyarrhythmias may require ablation.
  • Palpitations without arrhythmic causality or cardiac disease: reassurance; consider psychosomatic evaluation.
• Wearable smart devices with ambulatory ECG monitoring now available to consumers; can aid detection of arrhythmias and enable patient engagement, but with limitations.

Epidemiology and Prognosis

• Palpitations account for approximately $16 ext{ }\%$ of outpatient clinic visits and $0.6\%$ of emergency department visits.
• Among patients, lifetime risk of palpitations is about $10\%$.
• Palpitations reflect a spectrum from benign to potentially lethal etiologies; prognosis depends on underlying disease and clinical features.
• Patients with structural heart disease, arrhythmogenic conditions, or a family history of sudden cardiac death have potentially worse prognosis; palpitations without structural heart disease and without concerning symptoms generally have excellent prognosis.
• Recurrence rate for palpitations is about $75\%$, with recurrent episodes associated with impaired quality of life and increased health-care use.
• 1-year mortality for patients presenting with palpitations is approximately $1.6\%$.

Etiology and Differential (high-level)

• Palpitations have a broad differential; major categories include:
  • Cardiac arrhythmias: atrial fibrillation, atrial flutter, supraventricular tachycardia, premature atrial contractions, premature ventricular contractions, ventricular tachycardia/bradycardias;
  • Bradyarrhythmias: second- or third-degree AV block, sinus arrest, sinus bradycardia, sinus node dysfunction;
  • High-output states/elevated cardiac demand: anemia, fever, Paget disease, pregnancy, vascular shunts;
  • Structural heart disease: left/right ventricular failure, hypertrophic cardiomyopathy, valvular disease (mitral valve prolapse, regurgitation), congenital heart disease;
  • Syndromic and genetic conditions: Brugada syndrome, long QT syndrome, short QT syndrome, Wolff-Parkinson-White syndrome, ectopic syndromes;
  • Drug- and toxin-induced causes: caffeine, stimulants, illicit drugs, medications and withdrawal;
  • Metabolic/electrolyte disturbances: electrolytes, thyroid disorders, hypoxia/hypercapnia, pheochromocytoma;
  • Neurologic/autonomic: autonomic dysfunction (e.g., postural orthostatic tachycardia syndrome);
  • Psychosomatic: anxiety, panic disorder, somatization, heightened perception of normal heartbeat.
• Note: most common arrhythmia causing palpitations is atrial fibrillation (AF) among cardiac etiologies.

Diagnostic Evaluation (shared framework)

• Key predictors for palpitations of cardiac origin (multivariate analysis):
  • Male sex
  • Description of an “irregular” heartbeat
  • History of heart disease
  • Palpitations lasting >5 minutes
• History should cover:
  • Onset (sudden vs gradual), duration (instant, paroxysmal, sustained), quality, frequency
  • Triggers (activity, position, stress)
  • Associated symptoms (chest pain, nausea, shortness of breath, presyncope, syncope)
  • Ability to tap or reproduce rhythm to estimate rate/regularity
  • Personal medical history (cardiac disease, devices, thyroid disorders, COPD), family history of sudden cardiac death, social history, illicit drugs, and medications
• Physical examination: often non-diagnostic unless palpitations are occurring; still important to assess:
  • Vital signs and hemodynamic stability; orthostatic blood pressures
  • Cardiac and pulmonary examination; neck examination
  • Signs relevant to psychiatric health (eTable B)
• Diagnostic studies: baseline tests with 12-lead ECG and laboratory assessment are essential first steps. Consider additional tests based on clinical suspicion:
  • Laboratory: complete blood count, comprehensive metabolic panel, thyroid function, magnesium level, pregnancy test in women of reproductive age, toxicology screening
  • Cardiac biomarkers (troponin, B-type natriuretic peptide) usually not indicated unless sustained arrhythmia, ischemia concern, or hemodynamic instability
  • Chest radiography as needed for suspected cardiac disease

What’s New on This Topic

• Yoga and palpitations: structured yoga 45–60 minutes, at least 3 days/week, reduces palpitation episodes and premature ventricular contractions in arrhythmia cohorts.
• Consumer wearables: photoplethysmography or single-lead ECG devices detect AF and other arrhythmias but miss asymptomatic or very short episodes and have high false-positive rates.

Cardiac Investigations and Testing Details

• Twelve-lead ECG (12-ECG): initial test of choice; diagnostic yield for palpitations ranges $3\%$–$26\%$. If ECG documents a rhythm disorder during spontaneous symptoms, this provides strong evidence of causality.
  • When ECG is captured during palpitations, approximately $48\%$ show a rhythm abnormality.
• Echocardiography (Transthoracic): useful for evaluating structural heart disease; indicated with abnormal physical exam (e.g., displaced apical impulse, signs of heart failure, concerning murmur), abnormal ECG, syncope/presyncope, or family history of cardiomyopathy/sudden death.
• Cardiac stress testing: recommended if palpitations occur during or after exercise or if ischemic heart disease is suspected.
• Ambulatory ECG monitoring: if initial ECG is nondiagnostic and suspicion for an arrhythmia remains high; also indicated with structural heart disease history, family history of sudden cardiac death, or inherited channelopathies.
  • Typical monitoring durations and devices (Table 1):
  • Holter monitor: 24–48 hours; indicated for daily or near-daily symptoms; advantages: low cost, easy to use; limitations: bulky, artifact-prone
  • Event recorder: up to ~1 month; for weekly to monthly symptoms; advantages: small, easy to use; may miss brief arrhythmias
  • Patch monitors (e.g., Zio, CAM): continuous monitoring up to ~14 days; weekly symptoms; advantages: comfortable, can wear in shower/exercise; limitations: adhesive failure, single-use
  • Mobile cardiac telemetry: external loop recorder with real-time data; up to ~30 days; weekly symptoms; advantages: real-time transmission; limitations: requires internet proximity
  • Implantable loop recorder (ILR): under-skin device; 3-year battery life; for intermittent or infrequent symptoms, syncope, cryptogenic stroke monitoring; advantages: highest diagnostic yield; limitations: invasive, cost
  • Diagnostic yields: Holter 10–15%; external monitoring over 2 weeks yields 70–85%; implantable loop recorders yield 80–90% diagnostic yield; ILR is especially valuable when events are infrequent or recurrent syncope occurs.
• Electrophysiologic study (EPS): considered if ambulatory ECG monitoring remains nondiagnostic or when there is high suspicion for SVT; can be diagnostic and therapeutic (ablative) for SVTs (e.g., AVNRT, AVRT, or focal VT).
• Red flags (outpatient vs urgent): most palpitations are stable; however, urgent evaluation is required with hemodynamic instability or high-risk features (Table 2). Immediate transfer to ED with cardiology referral is indicated for ischemic chest pain, acute hypotension, signs of heart failure, decreased consciousness, or ischemic ECG changes.

Red Flags and Urgent Evaluation (Table 2)

• Family history of sudden cardiac death or inheritable conditions
• Hemodynamic instability with palpitations
• LV hypertrophy with aortic stenosis or hypertensive heart disease
• Palpitations with exercise or presyncope/syncope
• Syndromic ECG findings suggestive of inheritable arrhythmia syndromes (e.g., Brugada, HCM, Long QT, Short QT)
• Ischemic heart disease signs on ECG (Q waves, ischemic changes, poor R-wave progression)
• Long QT or short QT patterns; Wolff-Parkinson-White pattern (short PR with delta wave)
• Resting tachycardia >120 bpm
• High-degree AV block or ventricular conduction abnormalities
• Severe bradycardia or ventricular ectopy in the setting of structural heart disease

Management by Etiology (Table 3) and General Principles

• General principles: most palpitations are benign; management focuses on underlying cause, symptom burden, and risk of progression to a dangerous arrhythmia; discontinue drugs that provoke palpitations; address cardiac risk factors; provide stress-reduction strategies.
• Psychosomatic or noncardiac palpitations: reassurance; if symptoms persist, consider psychosomatic approaches (yoga, cognitive-behavioral therapy); pharmacologic mood stabilizers not routinely used; in some cases central alpha-2 agonists (e.g., clonidine) may help; avoid alpha-2 antagonists.
• Arrhythmia-associated palpitations: management depends on the specific rhythm disturbance and its hemodynamic impact. Key scenarios include:
  • Atrial fibrillation (AF): irregular, rapid rhythm; rate control with beta blockers or nondihydropyridine calcium-channel blockers; rhythm-control strategies include electrical or chemical cardioversion and ablation as definitive therapy; consider ablation for recurrent AF or failure of medical therapy.
  • Atrial flutter: regular rapid rhythm; rate control; ablation is often definitive therapy; poor rate control may require rhythm-control approaches.
  • Supraventricular tachycardia (SVT): rapid, regular rhythm with narrow QRS; management includes vagal maneuvers, adenosine, or electrical cardioversion; recurrent SVT often referred for ablation.
  • Premature atrial contractions (PACs): reassurance for isolated or infrequent cases; beta blockers may be used for low-burden PACs with symptoms; assess PAC burden with Holter monitoring; when PACs trigger atrial fibrillation, cardiology referral for antiarrhythmic or ablative therapy may be appropriate.
  • Premature ventricular contractions (PVCs): reassurance if isolated; for persistent symptoms or high ectopic burden, consider beta blockers or nondihydropyridine calcium-channel blockers; antiarrhythmics or ablation if symptomatic with preserved LV function; ablation if there is LV dysfunction or cardiomyopathy risk from ectopy.
  • Ventricular tachycardia (VT): if sustained or causing hemodynamic compromise, manage as per ACLS/advanced care protocols; if non-sustained VT and hemodynamically stable, ambulatory monitoring and cardiology input recommended.
  • Inappropriate sinus tachycardia: rest and reduced triggering factors; yoga or vagal maneuvers; consider nonselective beta blockers, calcium-channel blockers; ivabradine as an option; overlapping with postural tachycardia syndrome.
  • Sinus node dysfunction: age-related; symptom severity correlates with bradyarrhythmia; permanent pacing consideration.
• Specific notes on first-line therapy: reassurance and education are first-line for most patients; address modifiable risk factors and lifestyle; avoid adrenergic substances; consider stress-reduction techniques; structured yoga can reduce palpitations and ectopy in some patients.

Role of Psychosocial and Long-COVID Considerations

• Psychiatric comorbidity and palpitations: small studies show higher coexisting psychiatric disorders in palpitation patients; however, other physical etiologies must be excluded before attributing palpitations to psychosomatic causes.
• Long-COVID autonomic dysfunction can present with chest pain, orthostatic intolerance, and palpitations; evaluation should consider autonomic etiologies in the appropriate clinical context.
• Management emphasis on addressing psychosomatic components where appropriate, with integrated care involving cardiology and mental health as needed.

Wearable and Smartphone-Based Ambulatory Cardiac Monitoring (Table 4)

• Devices and capabilities (select examples):
  • AliveCor KardiaMobile: 30-second ECG, intermittent monitoring (every ~5 minutes); integrates with Apple Health/Google Fit; allows expert interpretation; AF detection sensitivity $92\%–100\%$, specificity $95\%–97\%$; overall arrhythmia detection ~$75\%$ diagnostic for palpitations (54\% with no arrhythmias; 20\% with palpitations and arrhythmia)
  • HeartCheck CardiBeat: 30-second ECG; AF detection; FDA clearance for AF
  • Apple Watch ECG: 30-second ECG; cardiac fitness sensor; SpO2; temperature tracking; fall detection; AF sensitivity around $98\%$ and specificity $99\%$; other ECG findings: ~$88\%$ sensitivity and $93\%$ specificity for any abnormal ECG; PVC detection sensitivity ~$55\%$ with specificity $98\%$; FDA-cleared for AF
  • Frontier X2: ECG recording up to 24 hours; continuous monitoring; waterproof; advertises detection of arrhythmias, ST-segment deviations, QT interval; not FDA-cleared as a medical device
  • Withings ScanWatch: 30-second ECG; intermittent monitoring every ~10 minutes; tracks resting HR, HRV, SpO2, sleep
• General conclusions about wearable devices:
  • High sensitivity and specificity for AF detection across many consumer devices, but limited capability to detect asymptomatic or very short episodes; risk of false positives can lead to unnecessary testing and anxiety.
  • Utility for palpitations: diagnostic yield varies; retrospective studies show a substantial proportion of arrhythmias detected, but many patients have no arrhythmia during monitoring.
  • Limitations and practical issues: devices require patient activation for ECG recording (limits detection of asymptomatic events); limited ability to detect all arrhythmias; data quality and artifacts; variable battery life; cost considerations; need for clinician notification, documentation, and reimbursement workflows when integrating consumer-device data into medical care.
• US preventive services task force (USPSTF) stance: as of 2022, no formal recommendation for general AF screening beyond existing guidelines; insufficient evidence to screen for other arrhythmias using these devices; observational data support AF detection in consumer devices but clinical utility for broader outcomes remains an area of active study (Heartline trial, etc.).
• Clinical implications and ongoing research:
  • Heartline study exploring whether early AF detection via wearables reduces thromboembolic events and improves cardiovascular outcomes.
  • Growing emphasis on how to integrate digital health data into routine care, including notification protocols, documentation, reimbursement, and coordination of care with arrhythmia detection from consumer devices.
• Practical considerations for clinicians:
  • When patients present with palpitations and wearables show AF or other arrhythmias, corroborate with clinical assessment, ECG, and, if indicated, ambulatory monitoring or EPS.
  • Be aware of limitations: asymptomatic AF, paroxysmal, or very brief episodes may be missed; false positives can occur; confirmatory testing recommended before therapeutic decisions.

Ambulatory ECG Monitoring Devices: Key Takeaways (Table 1 recap)

• Holter monitor: 24–48 hours; good for daily or near-daily symptoms; low cost; easily usable; limitations include bulky equipment and artifact.
• Event recorder: up to ~1 month; patient-activated; useful for weekly/monthly symptoms; small and discreet; limitations include potential to miss brief events and reliance on patient activation.
• Patch monitor (e.g., Zio, CAM patch): up to 14 days; comfortable; can be worn during shower/exercise; adhesive issues may occur; single-use.
• Mobile cardiac telemetry: external loop recorder with real-time data; up to ~30 days; requires good internet connectivity; proximity of sensor/receiver.
• Implantable loop recorder (ILR): under-skin device; 3-year battery life; highest diagnostic yield for palpitations (80–90%); invasive and costly; best for recurrent syncope or cryptogenic stroke monitoring when noninvasive methods fail.

Practical Algorithms in Primary Care (Figure 1 concepts)

• Stepwise approach to palpitations in primary care:
  1) Is the patient hemodynamically unstable? If yes, treat per ACLS and transfer to ED with cardiology involvement.
  2) Obtain history, physical exam, labs, and ECG; assess for red flags and noncardiac etiologies.
  3) If significant risk factors or abnormal findings suggest structural/ischemic heart disease, refer to cardiology for further evaluation (including echocardiography, stress testing as indicated).
  4) If noncardiac etiology suspected or if initial tests are normal, consider ambulatory ECG monitoring to capture intermittent events; use longer monitoring (e.g., 2 weeks external monitor or ILR) based on symptom frequency.
  5) If arrhythmia is documented, tailor therapy to the specific rhythm disturbance per Table 3; if no arrhythmia is found but symptoms persist, consider psychosomatic assessment and nonpharmacologic strategies.

Table 3: Treatment for Selected Etiologies of Palpitations (highlights)

• Atrial fibrillation: irregular, rapid rhythm; rate control with beta blockers or nondihydropyridine CCBs; rhythm control via electrical/chemical cardioversion; ablation for definitive therapy.
• Atrial flutter: regular rapid rhythm; rate control; catheter ablation often definitive therapy.
• Supraventricular tachycardia: rapid, regular rate with narrow QRS; vagal maneuvers, adenosine, or electrical cardioversion; ablation for recurrent episodes.
• Premature atrial contractions: reassurance; consider beta blocker if symptomatic or burden is significant; assess ectopic burden with Holter monitoring; PACs can trigger AF; cardiology referral for antiarrhythmic or ablation if relevant.
• Premature ventricular contractions: isolated/ occasional PVCs benign; if symptomatic or high burden with LV dysfunction, treat with beta blocker or non-DHP CCB; consider antiarrhythmic therapy or ablation if symptomatic; LV dysfunction prompts ablation consideration.
• Ventricular tachycardia and NSVT: depending on stability and LV function; manage accordingly with monitoring and cardiology input; ambulatory monitoring used for evaluation.
• Inappropriate sinus tachycardia: resting HR > 100 bpm; yoga/relaxation to increase vagal tone; consider nonselective beta blockers, calcium channel blockers, or ivabradine; overlaps with postural tachycardia syndrome.
• Psychosomatic palpitations: reassurance, yoga, cognitive-behavioral therapy; mood stabilizers only in selected cases.
• Pacing for sinus node dysfunction when appropriate; consider permanent pacing for symptomatic bradyarrhythmias.

Summary of Evolving Concepts

• Most palpitations are benign; however, a thorough evaluation is essential to rule out structural heart disease and malignant arrhythmias.
• A 12-lead ECG is essential in all patients; further imaging and monitoring are guided by clinical features.
• Ambulatory monitoring provides the highest diagnostic yield for unknown etiologies when symptoms are intermittent.
• Wearable technologies offer promising AF detection capabilities but require careful integration into clinical care due to limitations in detecting non-AF arrhythmias and potential false positives.

eTABLE A: Differential Diagnosis (condensed)

• Cardiac: atrial arrhythmias (AF, flutter, SVT), bradyarrhythmias, teleporting conduction issues, high-output states, cardiomyopathy-related changes; implanted devices misfunctioning.
• Structural: aortic and valvular disease, congenital heart disease, hypertrophic cardiomyopathy, prosthetic valves, myocardial/valvular abnormalities.
• Syndromic: Brugada, LQTS, SQT, WPW, systemic disorders.
• Ventricular arrhythmias: PVCs, VT, VF.
• Drug-induced: stimulants, caffeine, various medications and withdrawal
• Metabolic: electrolyte disturbances, thyroid disorders, hypoxia, hypercapnia, pheochromocytoma.
• Neurologic: autonomic dysfunction, vasovagal syncope.
• Psychosomatic: anxiety, depression, heightened heartbeat perception, panic.

eTABLE B: Clinical Findings and Possible Diagnoses (highlights)

• Personal history patterns:
  • Syncope/presyncope with palpitations often points to arrhythmias or autonomic causes; congenital/syndromic conditions increase suspicion for inherited tachyarrhythmias.
  • Palpitations with fast rate can indicate SVT, AF, or sinus tachycardia depending on regularity.
  • Rapid pounding in the neck may reflect PVCs or SVT (AVNRT).
• Symptom timing:
  • Onset during/after exercise suggests AF or tachyarrhythmias; palpitations at rest or with positional changes suggest sinus tachycardia or SVT variants.
• Triggers and risk factors:
  • Family history of sudden cardiac death raises concern for inherited arrhythmia syndromes; stimulant or sympathomimetic use can provoke PACs/PVCs or SVT.
• Physical examination clues:
  • Cannon A waves suggest AVNRT, complete heart block, or PVCs with dyssynchronous atrial contraction.
  • Displaced PMIs, murmurs, or signs of heart failure raise concern for structural disease.
  • Hyperthyroidism signs (goiter, exophthalmos, tachycardia) can contribute to palpitations.
• Other findings:
  • Second/third-degree AV block, LV hypertrophy, abnormal Q waves, or ischemic changes may indicate structural or ischemic etiologies.

Clinician Considerations and Practical Takeaways

• Use a structured framework combining history, exam, ECG, and selective testing to distinguish benign from potentially dangerous etiologies.
• Consider psychosomatic and autonomic etiologies especially when structural disease is not evident and palpitations occur in the context of heightened emotional states or autonomic symptoms.
• Employ ambulatory monitoring strategically based on symptom frequency and prior test results to maximize diagnostic yield while considering patient burden and cost.
• When integrating consumer wearables into care, validate clinically actionable findings with standard diagnostic workups and maintain patient education about device limitations.
• Stay current with guidelines and ongoing research (e.g., Heartline, USPSTF AF screening considerations) to guide screening and management decisions.